Citalopram updated on 07-01-2025

Abdominal wall defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8214
R25497		 Jordan, 2016 Abdominal wall defects 3 months or more before pregnancy or1st trimester excluded retrospective cohort (registry) unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.16 [0.37;3.64]
excluded (exposition period) 		3/4,028   275/506,155 278 4,028
ref
S5884
R14739		 Ban (Controls unexposed, disease free), 2014 Abdominal wall malformations 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.20 [0.07;19.43] C 0/1,946   69/325,294 69 1,946
ref
S6014
R15497		 Jimenez-Solem (Controls unexposed, NOS), 2012 Abdominal wall defects 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.54 [0.35;18.30] 1/1,606   -/843,797 - 1,606
ref
Total 2 studies 1.98 [0.39;9.91] 69 3,552
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ban (Controls unexposed, disease free), 2014Ban, 2014 1 1.20[0.07; 19.43]691,94634%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Jimenez-Solem (Controls unexposed, NOS), 2012Jimenez-Solem, 2012 2 2.54[0.35; 18.30]-1,60666%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: critical Total (2 studies) I2 = 0% 1.98[0.39; 9.91]693,5520.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free; 2: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.98[0.39; 9.91]693,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.98[0.39; 9.91]693,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 Tags Adjustment   - No  - No 1.20[0.07; 19.43]691,946 -NABan (Controls unexposed, disease free), 2014 1   - Yes  - Yes 2.54[0.35; 18.37]-1,606 -NAJimenez-Solem (Controls unexposed, NOS), 2012 1 Monotherapy   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.98[0.39; 9.91]693,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 2 All studiesAll studies 1.98[0.39; 9.91]693,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.98[0.39; 9.91]693,5520%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 20.510.01.0